{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:25:16Z","timestamp":1783988716558,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,19]]},"DOI":"10.7759\/cureus.43773","type":"journal-article","created":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T02:20:57Z","timestamp":1692498057000},"source":"Crossref","is-referenced-by-count":12,"title":["Acute Pancreatitis in a Patient Taking Semaglutide"],"prefix":"10.7759","author":[{"given":"Femina","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"America\u2019s Obesity Crisis: The Health and Economic Costs of Excess Weight","author":"Waters H\ufeff","year":"2018","unstructured":"Waters H\ufeff, Graf M. America\u2019s Obesity Crisis: The Health and Economic Costs of Excess Weight. Milken Institute, Santa Monica; 2018."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108656","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"172","author":"Li J","year":"2021","unstructured":"Li J, He K, Ge J, Li C, Jing Z. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2021, 172:108656. 10.1016\/j.diabres.2021.108656","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo JM","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021, 12:2042018821997320. 10.1177\/2042018821997320","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.09.008","article-title":"A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer","volume":"98","author":"Alves C","year":"2012","unstructured":"Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012, 98:271-84. 10.1016\/j.diabres.2012.09.008","journal-title":"Diabetes Res Clin Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff M","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011, 141:150-6. 10.1053\/j.gastro.2011.02.018","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh S","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013, 173:534-9. 10.1001\/jamainternmed.2013.2720","journal-title":"JAMA Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12297","article-title":"A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position","volume":"16","author":"Giorda CB","year":"2014","unstructured":"Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014, 16:1041-7. 10.1111\/dom.12297","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty R","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr. 2022, 16:102427. 10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Syndr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0386-8","article-title":"Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies","volume":"48","author":"Giorda CB","year":"2015","unstructured":"Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015, 48:461-71. 10.1007\/s12020-014-0386-8","journal-title":"Endocrine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard H","year":"2017","unstructured":"Storgaard H, Cold F, Gluud LL, Vilsb\u00f8ll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017, 19:906-8. 10.1111\/dom.12885","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials","volume":"68","author":"Cao C","year":"2020","unstructured":"Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine. 2020, 68:518-25. 10.1007\/s12020-020-02223-6","journal-title":"Endocrine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12833","article-title":"Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study","volume":"19","author":"Knapen LM","year":"2017","unstructured":"Knapen LM, de Jong RG, Driessen JH, et al.. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017, 19:401-11. 10.1111\/dom.12833","journal-title":"Diabetes Obes Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2983","article-title":"Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study","volume":"38","author":"Thomsen RW","year":"2015","unstructured":"Thomsen RW, Pedersen L, M\u00f8ller N, Kahlert J, Beck-Nielsen H, S\u00f8rensen HT. Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study. Diabetes Care. 2015, 38:1089-98. 10.2337\/dc13-2983","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-013-0544-0","article-title":"Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case\/non-case study from the French Pharmacovigilance Database","volume":"51","author":"Faillie JL","year":"2014","unstructured":"Faillie JL, Babai S, Cr\u00e9pin S, et al.. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case\/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014, 51:491-7. 10.1007\/s00592-013-0544-0","journal-title":"Acta Diabetol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.03.019","article-title":"Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies","volume":"20","author":"Aune D","year":"2020","unstructured":"Aune D, Mahamat-Saleh Y, Norat T, Riboli E. Diabetes mellitus and the risk of pancreatitis: a systematic review and meta-analysis of cohort studies. Pancreatology. 2020, 20:602-7. 10.1016\/j.pan.2020.03.019","journal-title":"Pancreatology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/178616-acute-pancreatitis-in-a-patient-taking-semaglutide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:26Z","timestamp":1707508526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/178616-acute-pancreatitis-in-a-patient-taking-semaglutide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.43773","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,19]]}}}